New Diagnostic Tool for Metastatic Prostate Cancer Advances Following License Agreement

New Diagnostic Tool for Metastatic Prostate Cancer Advances Following License Agreement
The development of CTT1057, a new product for the diagnosis of metastatic prostate cancer, received a boost with the worldwide license agreement between Novartis-held company Advanced Accelerator Applications (AAA) and Cancer Targeted Technology (CTT). Men with prostate cancer typically show elevated blood levels of prostate-specific antigen (PSA). Screening for PSA levels is common in men

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *